<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Polymorphisms in Turkish population &#187; Methods</title>
	<atom:link href="http://polymorphisms.info/tag/methods/feed" rel="self" type="application/rss+xml" />
	<link>http://polymorphisms.info</link>
	<description></description>
	<lastBuildDate>Thu, 19 May 2011 20:57:51 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.1</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Analysis of paraoxonase 1 (PON1) genetic polymorphisms and activities as risk factors for ischemic stroke in Turkish population</title>
		<link>http://polymorphisms.info/gene-polymorphisms/paraoxonase-gene-polymorphisms/analysis-of-paraoxonase-1-pon1-genetic-polymorphisms-and-activities-as-risk-factors-for-ischemic-stroke-in-turkish-population.html</link>
		<comments>http://polymorphisms.info/gene-polymorphisms/paraoxonase-gene-polymorphisms/analysis-of-paraoxonase-1-pon1-genetic-polymorphisms-and-activities-as-risk-factors-for-ischemic-stroke-in-turkish-population.html#comments</comments>
		<pubDate>Wed, 20 Jan 2010 23:49:50 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Paraoxonase]]></category>
		<category><![CDATA[Abstract]]></category>
		<category><![CDATA[abstract background]]></category>
		<category><![CDATA[adali]]></category>
		<category><![CDATA[arinc]]></category>
		<category><![CDATA[ATHEROSCLEROSIS]]></category>
		<category><![CDATA[Aysun]]></category>
		<category><![CDATA[Biochemistry]]></category>
		<category><![CDATA[birsen]]></category>
		<category><![CDATA[Caucasian]]></category>
		<category><![CDATA[caucasian patients]]></category>
		<category><![CDATA[cell biochemistry and function]]></category>
		<category><![CDATA[CHOLESTEROL]]></category>
		<category><![CDATA[Copyright]]></category>
		<category><![CDATA[Demirdogen]]></category>
		<category><![CDATA[Demirkaya]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[elderly age]]></category>
		<category><![CDATA[elderly population]]></category>
		<category><![CDATA[emel]]></category>
		<category><![CDATA[english author]]></category>
		<category><![CDATA[enzyme]]></category>
		<category><![CDATA[enzyme activities]]></category>
		<category><![CDATA[FUNCTION]]></category>
		<category><![CDATA[genotype]]></category>
		<category><![CDATA[Genotypes]]></category>
		<category><![CDATA[Gulhane]]></category>
		<category><![CDATA[haplotype]]></category>
		<category><![CDATA[increase]]></category>
		<category><![CDATA[ischemic stroke]]></category>
		<category><![CDATA[john wiley sons]]></category>
		<category><![CDATA[LIPID-PEROXIDATION]]></category>
		<category><![CDATA[LOW-DENSITY-LIPOPROTEIN]]></category>
		<category><![CDATA[Methods]]></category>
		<category><![CDATA[Middle]]></category>
		<category><![CDATA[PCR]]></category>
		<category><![CDATA[polymorphism]]></category>
		<category><![CDATA[PON]]></category>
		<category><![CDATA[restriction]]></category>
		<category><![CDATA[restriction enzyme digestion]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Saydam]]></category>
		<category><![CDATA[semai]]></category>
		<category><![CDATA[stroke patients]]></category>
		<category><![CDATA[THICKNESS]]></category>
		<category><![CDATA[Triple]]></category>
		<category><![CDATA[Turkanoglu]]></category>
		<category><![CDATA[Volume]]></category>

		<guid isPermaLink="false">http://polymorphisms.info/?p=288</guid>
		<description><![CDATA[Author(s): Demirdogen BC (Demirdogen, Birsen Can)1, Demirkaya S (Demirkaya, Seref)2, Turkanoglu A (Turkanoglu, Aysun)1, Bek S (Bek, Semai)2, Arinc E (Arinc, Emel)1, Adali O (Adali, Orhan)1
Source: CELL BIOCHEMISTRY AND FUNCTION    Volume: 27    Issue: 8    Pages: 558-567    Published: DEC 2009    
 [...]]]></description>
			<content:encoded><![CDATA[<p>Author(s): Demirdogen BC (Demirdogen, Birsen Can)1, Demirkaya S (Demirkaya, Seref)2, Turkanoglu A (Turkanoglu, Aysun)1, Bek S (Bek, Semai)2, Arinc E (Arinc, Emel)1, Adali O (Adali, Orhan)1<br />
Source: CELL BIOCHEMISTRY AND FUNCTION    Volume: 27    Issue: 8    Pages: 558-567    Published: DEC 2009    </p>
<p> Abstract: Background Paraoxonase 1 (PON1) is protective against the development of atherosclerosis. a risk factor for ischemic stroke. PON1 gene has one promoter region (-107T/C) and two coding region (192Q/R and 55L/M) polymorphisms that affect the levels and catalytic efficiency of the enzyme. respectively. In this study. we aimed to determine the importance of -107T/C. 192Q/R and 55L/M polymorphisms of PON1 gene and three PON1 activity (diazoxonase, paraoxonase, arylesterase) as risk factors for ischemic stroke<br />
Methods Stud population was comprised of 172 unrelated adult Caucasian patients with acute hemispheric ischemic stroke and 105 symptom-free controls. Genotypes were attained by PCR followed by restriction enzyme digestion and phenotypes were determined by spectrophotometric assays.</p>
<p>Results This is the first study analyzing diazoxonase activity as a risk factor for ischemic stroke Nevertheless, diazoxonase, paraoxonase and arylesterase activities were almost the manic in stroke patients and controls The 107TT genotype was associated with a 1 97 times increased risk for stroke in elderly (age > 59). Individuals with this genotype were found to have the lowest PON1 enzyme activities among the -107T/C genotypes Triple combined haplotype QRLMTC was found to be 6.94- and 10.4-times protective against ischemic stroke in the overall and the elderly Population. respectively. 55LL genotype was associated with 1 78-fold increase in the risk of ischemic stroke</p>
<p>Conclusion PON1 genotypes, but not activities, are related with the risk of stroke. Copyright (C) 2009 John Wiley &#038; Sons, Ltd</p>
<p>Document Type: Article<br />
Language: English<br />
Author Keywords: genotype; paraoxonase; PON1; polymorphism; stroke<br />
KeyWords Plus: HUMAN-SERUM PARAOXONASE; LOW-DENSITY-LIPOPROTEIN; INTIMA-MEDIA THICKNESS; LIPID-PEROXIDATION; LDL OXIDATION; ARYLESTERASE; PROMOTER; PROTEIN; ATHEROSCLEROSIS; CHOLESTEROL<br />
Reprint Address: Demirdogen, BC (reprint author), Refik Saydam Natl Publ Hlth Agcy, Directorate Food Safety &#038; Nutr Res, Ankara, Turkey<br />
Addresses:<br />
1. Middle E Tech Univ, Dept Biochem, Inst Nat &#038; Appl Sci, TR-06531 Ankara, Turkey<br />
2. Gulhane Mil Med Acad, Dept Neurol, Ankara, Turkey  </p>
]]></content:encoded>
			<wfw:commentRss>http://polymorphisms.info/gene-polymorphisms/paraoxonase-gene-polymorphisms/analysis-of-paraoxonase-1-pon1-genetic-polymorphisms-and-activities-as-risk-factors-for-ischemic-stroke-in-turkish-population.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Common MEFV mutations and polymorphisms in an elderly population: an association with E148Q polymorphism andrheumatoid factor levels.</title>
		<link>http://polymorphisms.info/cancer-kanser/common-mefv-mutations-and-polymorphisms-in-an-elderly-population-an-association-with-e148q-polymorphism-andrheumatoid-factor-levels-2.html</link>
		<comments>http://polymorphisms.info/cancer-kanser/common-mefv-mutations-and-polymorphisms-in-an-elderly-population-an-association-with-e148q-polymorphism-andrheumatoid-factor-levels-2.html#comments</comments>
		<pubDate>Mon, 24 Aug 2009 20:48:04 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer (Kanser)]]></category>
		<category><![CDATA[analyse]]></category>
		<category><![CDATA[association]]></category>
		<category><![CDATA[Beger]]></category>
		<category><![CDATA[Biology]]></category>
		<category><![CDATA[Bolayirli]]></category>
		<category><![CDATA[Center]]></category>
		<category><![CDATA[Clin]]></category>
		<category><![CDATA[Curgunlu]]></category>
		<category><![CDATA[Dasdemir]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DNA]]></category>
		<category><![CDATA[Erdincler]]></category>
		<category><![CDATA[Genetics]]></category>
		<category><![CDATA[hsCRP]]></category>
		<category><![CDATA[Karaca]]></category>
		<category><![CDATA[Karaman]]></category>
		<category><![CDATA[Mediterranean]]></category>
		<category><![CDATA[Methods]]></category>
		<category><![CDATA[PCR-RFLP]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[rheumatoid]]></category>
		<category><![CDATA[Rheumatol]]></category>
		<category><![CDATA[Technical]]></category>
		<category><![CDATA[Turanli]]></category>
		<category><![CDATA[Turkey]]></category>
		<category><![CDATA[Yazici]]></category>

		<guid isPermaLink="false">http://polymorphisms.info/?p=252</guid>
		<description><![CDATA[Clin Exp Rheumatol. 2009 Mar-Apr;27(2):340-3. Links

Turanli ET, Beger T, Erdincler D, Curgunlu A, Karaman S, Karaca E, Dasdemir S, Bolayirli M, Yazici H.
Department of Molecular Biology and Genetics, and 2Molecular Biology and Biotechnology Research Center, Istanbul Technical University, Istanbul, Turkey. turanlie@itu.edu.tr
OBJECTIVES: To analyse the most common MEFV (Mediterranean fever gene) mutations and polymorphisms in an [...]]]></description>
			<content:encoded><![CDATA[<p><span title="Clinical and experimental rheumatology.">Clin Exp Rheumatol.</span> 2009 Mar-Apr;27(2):340-3.<span class="linkbar"><script></script> Links</span></p>
<dd class="abstract">
<div class="authors"><!--AuthorList--><strong>Turanli ET</strong>, <strong>Beger T</strong>, <strong>Erdincler D</strong>, <strong>Curgunlu A</strong>, <strong>Karaman S</strong>, <strong>Karaca E</strong>, <strong>Dasdemir S</strong>, <strong>Bolayirli M</strong>, <strong>Yazici H</strong>.</div>
<p class="affiliation">Department of Molecular Biology and Genetics, and 2Molecular Biology and Biotechnology Research Center, Istanbul Technical University, Istanbul, Turkey. turanlie@itu.edu.tr</p>
<p class="abstract">OBJECTIVES: To analyse the most common MEFV (Mediterranean fever gene) mutations and polymorphisms in an elderly population free of chronic inflammatory disease (n=164), and explore possible associations between hsCRP (high sensitive C-reactive protein) and RF (rheumatoid factor) levels with MEFV mutations and polymorphisms. METHODS: An elderly group free of chronic inflammatory disease was chosen among the outpatients of the division of geriatric medicine. Total genomic DNA was isolated from blood, and PCR-RFLP analysis was performed using established protocols. Sera were analyzed for hsCRP and RF levels. RESULTS: The frequencies for 694V (1.8%), 694I (1.8%), 680I (0.6%), 726A (2.1%) and 148Q (5%) alleles were found to be similar to Turkish historic controls, with a carrier frequency of 1/4. Further analyses with rheumatoid factor (RF) levels and mutations revealed a significant association between the presence of the E148Q polymorphism with increased RF levels (&gt;15 mg/dl) (xi2= 7.358, p=0.007, OR=5.41 95% CI 1.41-20.64). CONCLUSIONS: Common MEFV mutations and polymorphisms were similarly represented among the elderly population compared to historic controls. On the other hand, a significant association was found between the presence of E148Q polymorphism and increased RF levels. This suggests that the previously noted increased RF levels in elderly populations may somehow be related to the now described association of RF with MEFV E148Q polymorphism.</p>
</dd>
]]></content:encoded>
			<wfw:commentRss>http://polymorphisms.info/cancer-kanser/common-mefv-mutations-and-polymorphisms-in-an-elderly-population-an-association-with-e148q-polymorphism-andrheumatoid-factor-levels-2.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The clinical significance of parathyroid tissue calcium sensing receptor gene polymorphisms and expression levels in end-stage renal disease patients.</title>
		<link>http://polymorphisms.info/gene-polymorphisms/the-clinical-significance-of-parathyroid-tissue-calcium-sensing-receptor-gene-polymorphisms-and-expression-levels-in-end-stage-renal-disease-patients.html</link>
		<comments>http://polymorphisms.info/gene-polymorphisms/the-clinical-significance-of-parathyroid-tissue-calcium-sensing-receptor-gene-polymorphisms-and-expression-levels-in-end-stage-renal-disease-patients.html#comments</comments>
		<pubDate>Mon, 24 Aug 2009 20:40:18 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Gene polymorphisms]]></category>
		<category><![CDATA[polymorphisms]]></category>
		<category><![CDATA[Berber]]></category>
		<category><![CDATA[expression]]></category>
		<category><![CDATA[hormone]]></category>
		<category><![CDATA[Istanbul]]></category>
		<category><![CDATA[Kara]]></category>
		<category><![CDATA[Marmara]]></category>
		<category><![CDATA[Methods]]></category>
		<category><![CDATA[Molecular]]></category>
		<category><![CDATA[parathyroid]]></category>
		<category><![CDATA[PCR]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[PTH]]></category>
		<category><![CDATA[receptor]]></category>
		<category><![CDATA[Sevinç]]></category>
		<category><![CDATA[Tellioglu]]></category>
		<category><![CDATA[Titiz]]></category>
		<category><![CDATA[Transplantation]]></category>
		<category><![CDATA[Turan]]></category>
		<category><![CDATA[Turkey]]></category>
		<category><![CDATA[University]]></category>

		<guid isPermaLink="false">http://polymorphisms.info/?p=244</guid>
		<description><![CDATA[Clin Nephrol. 2009 Aug;72(2):114-21. 

Eren PA, Turan K, Berber I, Canbakan M, Kara M, Tellioglu G, Bugan U, Sevinç C, Turkmen F, Titiz MI.
1Departments of Molecular Genetics and 3Transplantation, Haydarpasa Numune Research and Training Hospital, and 2Department of Basic Sciences, Faculty of Pharmacy, Marmara University, Istanbul, Turkey.
Background: The calcium sending receptor (CaSR) allows parathyroid and [...]]]></description>
			<content:encoded><![CDATA[<p><span title="Clinical nephrology.">Clin Nephrol.</span> 2009 Aug;72(2):114-21.<span class="linkbar"><script></script> </span></p>
<dd class="abstract">
<div class="authors"><!--AuthorList--><strong>Eren PA</strong>, <strong>Turan K</strong>, <strong>Berber I</strong>, <strong>Canbakan M</strong>, <strong>Kara M</strong>, <strong>Tellioglu G</strong>, <strong>Bugan U</strong>, <strong>Sevinç C</strong>, <strong>Turkmen F</strong>, <strong>Titiz MI</strong>.</div>
<p class="affiliation">1Departments of Molecular Genetics and 3Transplantation, Haydarpasa Numune Research and Training Hospital, and 2Department of Basic Sciences, Faculty of Pharmacy, Marmara University, Istanbul, Turkey.</p>
<p class="abstract">Background: The calcium sending receptor (CaSR) allows parathyroid and kidney tubular cells to regulate PTH secretion and tubular calcium reabsorption. In the present report, we examined the relationship between CaSR gene polymorphisms and parathyroid CaSR expression and serum calcium/parathyroid hormone (PTH) levels and clinical progress in ESRD patients in the Turkish population. Methods: We genotyped the CaSR R990G and Q1011E variants in 192 end-stage renal disease (ESRD) patients by allele-specific PCR. CaSR expression in parathyroid tissues of operated 33 patients was quantified with quantitative reverse transcription-PCR. Results: Compared with other genotypes, the ratio of both codon 990-AA and 1011-CC polymorphisms was found higher in operated patients (p = 0.001). In the total patient group PTH levels were found higher in patients with CC1011 genotype than those with CG1011 (1015.15 +/- 925.41 pg/ml; 523.84 +/- 544.6 pg/ml, respectively, p = 0.002). There were statistically important higher Ca2+ levels in the AA990 allele carrying cases than AG990 positive ones (9.3 +/- 1.0 mg/dl vs. 8.8 +/- 0.9, p = 0.006). On the other hand, the expression of CaSR in parathyroid tissue was found inversely proportional with serum PTH level (r = -0.71). Conclusion: Present data suggest that co-presence of CaSR gene AA990 and CC1011 alleles is a possible risk factor for bad prognosis in secondary hyperparathyroidism. Patients carrying this genotype have tendency to require operation early in their medical therapy period and need postoperative close follow up for possible recurrences.</p>
</dd>
]]></content:encoded>
			<wfw:commentRss>http://polymorphisms.info/gene-polymorphisms/the-clinical-significance-of-parathyroid-tissue-calcium-sensing-receptor-gene-polymorphisms-and-expression-levels-in-end-stage-renal-disease-patients.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nitric oxide synthase gene polymorphisms in children with minimal change nephrotic syndrome.</title>
		<link>http://polymorphisms.info/nitric-oxide-synthase/nitric-oxide-synthase-gene-polymorphisms-in-children-with-minimal-change-nephrotic-syndrome.html</link>
		<comments>http://polymorphisms.info/nitric-oxide-synthase/nitric-oxide-synthase-gene-polymorphisms-in-children-with-minimal-change-nephrotic-syndrome.html#comments</comments>
		<pubDate>Wed, 29 Apr 2009 19:31:31 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Nitric oxide synthase]]></category>
		<category><![CDATA[Alasehirli]]></category>
		<category><![CDATA[CONCLUSIONS]]></category>
		<category><![CDATA[Eighty-six]]></category>
		<category><![CDATA[endothelial]]></category>
		<category><![CDATA[frequency]]></category>
		<category><![CDATA[Gaziantep]]></category>
		<category><![CDATA[genotype]]></category>
		<category><![CDATA[MATERIALS]]></category>
		<category><![CDATA[Methods]]></category>
		<category><![CDATA[neuronal]]></category>
		<category><![CDATA[Pediatr]]></category>
		<category><![CDATA[Pharmacology]]></category>
		<category><![CDATA[polymerase]]></category>
		<category><![CDATA[polymorphism]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[syndrome]]></category>
		<category><![CDATA[synthase]]></category>
		<category><![CDATA[Turkey]]></category>
		<category><![CDATA[University]]></category>

		<guid isPermaLink="false">http://polymorphisms.info/?p=224</guid>
		<description><![CDATA[Pediatr Int. 2009 Feb;51(1):75-8.

Alasehirli B, Balat A, Barlas O, Kont A.
Department of Pharmacology, Medical Faculty, Gaziantep University, Gaziantep, Turkey.
AIMS: Nitric oxide (NO) attenuates many functions within the kidney, and all NO synthase (NOS) isoforms are constitutively expressed in the kidney. But the exact role of NO in renal diseases is still debatable. The aim of [...]]]></description>
			<content:encoded><![CDATA[<h2><span title="Pediatrics international : official journal of the Japan Pediatric Society."><a href="javascript:AL_get(this, 'jour', 'Pediatr Int.');">Pediatr Int.</a></span> 2009 Feb;51(1):75-8.</h2>
<div class="authors"><!--AuthorList--></div>
<div class="authors"><a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Alasehirli%20B%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Alasehirli B</strong></a>, <a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Balat%20A%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Balat A</strong></a>, <a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Barlas%20O%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Barlas O</strong></a>, <a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Kont%20A%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Kont A</strong></a>.</div>
<p class="affiliation">Department of Pharmacology, Medical Faculty, Gaziantep University, Gaziantep, Turkey.</p>
<p class="abstract">AIMS: Nitric oxide (NO) attenuates many functions within the kidney, and all NO synthase (NOS) isoforms are constitutively expressed in the kidney. But the exact role of NO in renal diseases is still debatable. The aim of the present study was to investigate endothelial (eNOS), and neuronal (nNOS) NOS gene polymorphisms in children with minimal change nephrotic syndrome (MCNS). MATERIALS AND METHODS: Eighty-six Turkish children with clinical MCNS, ranging in age from 2 to 10 years, were compared with 114 healthy age- and sex-matched controls. The glu 298 Asp (G/T) polymorphism of the eNOS, and C276T (C/T) polymorphism of nNOS genes were genotyped using polymerase chain reaction. RESULTS: The distribution of GG, TG, and TT genotypes for eNOS was 52%, 33% and 15% in MCNS compared with 61%, 26% and 13% in the controls (P &gt; 0.05). The distribution of CC, TC, and TT genotypes for nNOS was 16%, 66% and 18% in MCNS compared with 10%, 43% and 47% in the controls. TT genotype distribution of nNOS was found to be lower in patients (P = 0.003). The eNOS and nNOS gene polymorphisms were not associated with gender, positive family history, frequency of relapses, or response to steroid. CONCLUSIONS: The present study is the first to investigate eNOS and nNOS gene polymorphisms in children with MCNS. The nNOS gene polymorphism may be associated with MCNS in children, but further studies in a larger population with different glomerular diseases are needed to confirm the results.</p>
]]></content:encoded>
			<wfw:commentRss>http://polymorphisms.info/nitric-oxide-synthase/nitric-oxide-synthase-gene-polymorphisms-in-children-with-minimal-change-nephrotic-syndrome.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Interleukin-10 gene polymorphism in patients with papillary thyroid cancer in Turkish population.</title>
		<link>http://polymorphisms.info/cancer-kanser/thyroid-cancer-tiroid-kanseri/interleukin-10-gene-polymorphism-in-patients-with-papillary-thyroid-cancer-in-turkish-population.html</link>
		<comments>http://polymorphisms.info/cancer-kanser/thyroid-cancer-tiroid-kanseri/interleukin-10-gene-polymorphism-in-patients-with-papillary-thyroid-cancer-in-turkish-population.html#comments</comments>
		<pubDate>Thu, 04 Dec 2008 23:08:57 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Thyroid cancer(Tiroid kanseri)]]></category>
		<category><![CDATA[allelic frequencies]]></category>
		<category><![CDATA[Berdeli]]></category>
		<category><![CDATA[biological role]]></category>
		<category><![CDATA[Bornova]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Chronic]]></category>
		<category><![CDATA[chronic inflammation]]></category>
		<category><![CDATA[control groups]]></category>
		<category><![CDATA[cytokine]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DESIGN]]></category>
		<category><![CDATA[difference]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[drmerdogan]]></category>
		<category><![CDATA[Endocrinology]]></category>
		<category><![CDATA[endocrinology and metabolism]]></category>
		<category><![CDATA[factor]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[Gene polymorphisms]]></category>
		<category><![CDATA[genotype]]></category>
		<category><![CDATA[germ line]]></category>
		<category><![CDATA[inflammation]]></category>
		<category><![CDATA[inflammatory response]]></category>
		<category><![CDATA[interleukin 10]]></category>
		<category><![CDATA[Izmir]]></category>
		<category><![CDATA[izmir turkey]]></category>
		<category><![CDATA[J Endocrinol]]></category>
		<category><![CDATA[Karadeniz]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[metabolism]]></category>
		<category><![CDATA[Methods]]></category>
		<category><![CDATA[ozbek]]></category>
		<category><![CDATA[Ozgen]]></category>
		<category><![CDATA[papillary thyroid cancer]]></category>
		<category><![CDATA[polymorphism]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[population research]]></category>
		<category><![CDATA[proinflammatory]]></category>
		<category><![CDATA[PTC]]></category>
		<category><![CDATA[regulation]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[restriction fragment length]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[thyroid]]></category>
		<category><![CDATA[turkish population]]></category>
		<category><![CDATA[University]]></category>
		<category><![CDATA[university medical school]]></category>

		<guid isPermaLink="false">http://polymorphisms.info/?p=179</guid>
		<description><![CDATA[ 
 J Endocrinol Invest. 2008 Sep;31(9):750-4.

Erdogan M, Karadeniz M, Ozbek M, Ozgen AG, Berdeli A.
Department of Endocrinology and Metabolism Disease, Ege University Medical School, Bornova, Izmir, Turkey. drmerdogan61@yahoo.com
OBJECTIVE: Interleukin-10 (IL-10) is a major anti-inflammatory cytokine that plays a crucial role in the regulation of the immune system. Chronic inflammation has been reported to be a [...]]]></description>
			<content:encoded><![CDATA[<p> </p>
<p><strong> </strong><span title="Journal of endocrinological investigation."><a href="javascript:AL_get(this, 'jour', 'J Endocrinol Invest.');">J Endocrinol Invest.</a></span> 2008 Sep;31(9):750-4.<script></script></p>
<dd class="abstract">
<div class="authors"><!--AuthorList--><a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Erdogan%20M%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Erdogan M</strong></a>, <a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Karadeniz%20M%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Karadeniz M</strong></a>, <a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Ozbek%20M%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Ozbek M</strong></a>, <a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Ozgen%20AG%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Ozgen AG</strong></a>, <a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Berdeli%20A%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Berdeli A</strong></a>.</div>
<p class="affiliation">Department of Endocrinology and Metabolism Disease, Ege University Medical School, Bornova, Izmir, Turkey. drmerdogan61@yahoo.com</p>
<p class="abstract">OBJECTIVE: Interleukin-10 (IL-10) is a major anti-inflammatory cytokine that plays a crucial role in the regulation of the immune system. Chronic inflammation has been reported to be a risk factor for thyroid neoplasia. The propensity to mount an inflammatory response is modified by germ line variation in cytokine and other inflammation-related genes. We hypothesized that a proinflammatory genotype would be positively associated with thyroid cancer. We aimed to evaluate the relation between the genotypic and allelic frequencies of the IL-10(-1082 G/A), IL-10(-592 A/C), and IL-10(-819 C/T) polymorphisms, and their association with the risk of developing papillary thyroid cancer (PTC) in the Turkish population. RESEARCH DESIGN AND METHODS: Forty-two patients with PTC and 113 healthy controls were included in this study. The diagnosis of PTC was confirmed by histopathologic examination after surgery. The evaluation of genotype for IL-10 gene polymorphism was performed using PCR-restriction fragment length polymorphism method. RESULTS: Statistically significant difference IL-10(-1082 G/A) gene polymorphism was determined between 2 (PTC and control) groups. No difference was determined with respect to IL-10(-592 A/C) and IL-10(-819 C/T) gene polymorphisms, and IL-10(-1082 G/A), IL-10(-592 A/C), and IL-10(-819 C/T) allele frequencies of participating between the control group and the patients with PTC (p&gt;0.05). CONCLUSIONS: The polymorphism of IL-10(-1082 G/A) gene was significantly associated with the occurrence of PTC. Such studies will contribute significantly to our understanding of the biological role of IL-10(-1082 G/A) gene polymorphism in PTC development. In conclusion, IL-10(-1082 G/A) gene polymorphism may affect the survival of papillary thyroid carcinoma.</p>
</dd>
]]></content:encoded>
			<wfw:commentRss>http://polymorphisms.info/cancer-kanser/thyroid-cancer-tiroid-kanseri/interleukin-10-gene-polymorphism-in-patients-with-papillary-thyroid-cancer-in-turkish-population.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations.</title>
		<link>http://polymorphisms.info/polymorphisms/comparison-of-slco1b1-sequence-variability-among-german-turkish-and-african-populations.html</link>
		<comments>http://polymorphisms.info/polymorphisms/comparison-of-slco1b1-sequence-variability-among-german-turkish-and-african-populations.html#comments</comments>
		<pubDate>Fri, 05 Sep 2008 12:27:35 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[polymorphisms]]></category>
		<category><![CDATA[african populations]]></category>
		<category><![CDATA[african subjects]]></category>
		<category><![CDATA[analysis]]></category>
		<category><![CDATA[basis]]></category>
		<category><![CDATA[berlin germany]]></category>
		<category><![CDATA[bile acids]]></category>
		<category><![CDATA[block structure]]></category>
		<category><![CDATA[Epub]]></category>
		<category><![CDATA[extraction]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[gene sequence]]></category>
		<category><![CDATA[Germany]]></category>
		<category><![CDATA[haplotype]]></category>
		<category><![CDATA[hepatocellular]]></category>
		<category><![CDATA[Humboldt]]></category>
		<category><![CDATA[Institute]]></category>
		<category><![CDATA[J Clin]]></category>
		<category><![CDATA[j clin pharmacol]]></category>
		<category><![CDATA[Köpke]]></category>
		<category><![CDATA[linkage disequilibrium]]></category>
		<category><![CDATA[liver]]></category>
		<category><![CDATA[Methods]]></category>
		<category><![CDATA[nucleotide]]></category>
		<category><![CDATA[PCR]]></category>
		<category><![CDATA[Pharmacology]]></category>
		<category><![CDATA[portal]]></category>
		<category><![CDATA[RFLP]]></category>
		<category><![CDATA[Roots]]></category>
		<category><![CDATA[Schaefer]]></category>
		<category><![CDATA[Schumannstrasse]]></category>
		<category><![CDATA[sequence]]></category>
		<category><![CDATA[SLCO]]></category>
		<category><![CDATA[SNPs]]></category>
		<category><![CDATA[Universitätsmedizin]]></category>
		<category><![CDATA[xenobiotics]]></category>

		<guid isPermaLink="false">http://polymorphisms.info/?p=175</guid>
		<description><![CDATA[Eur J Clin Pharmacol. 2008 Mar;64(3):257-66. Epub 2008 Jan 6.

Mwinyi J, Köpke K, Schaefer M, Roots I, Gerloff T.
Institute of Clinical Pharmacology, Charité-Universitätsmedizin Berlin, Humboldt University of Berlin, Schumannstrasse 20/21, 10098 Berlin, Germany.
BACKGROUND: OATP1B1 is one of the key hepatocellular uptake transporters providing extraction of diverse compounds, including bile acids, xenobiotics, and a variety of [...]]]></description>
			<content:encoded><![CDATA[<p><span title="European journal of clinical pharmacology."><a href="javascript:AL_get(this, 'jour', 'Eur J Clin Pharmacol.');">Eur J Clin Pharmacol.</a></span> 2008 Mar;64(3):257-66. Epub 2008 Jan 6.<script></script></p>
<dd class="abstract">
<div class="authors"><!--AuthorList--><a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Mwinyi%20J%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Mwinyi J</strong></a>, <a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22K%C3%B6pke%20K%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Köpke K</strong></a>, <a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Schaefer%20M%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Schaefer M</strong></a>, <a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Roots%20I%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Roots I</strong></a>, <a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Gerloff%20T%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Gerloff T</strong></a>.</div>
<p class="affiliation">Institute of Clinical Pharmacology, Charité-Universitätsmedizin Berlin, Humboldt University of Berlin, Schumannstrasse 20/21, 10098 Berlin, Germany.</p>
<p class="abstract" style="text-align: justify;">BACKGROUND: OATP1B1 is one of the key hepatocellular uptake transporters providing extraction of diverse compounds, including bile acids, xenobiotics, and a variety of drugs, from portal venous blood into the liver. Polymorphisms of the SLCO1B1 gene have been demonstrated to influence in vitro transport function and the pharmacokinetic profile of compounds. OBJECTIVE: The goal of our study was the comparison of SLCO1B1 gene sequence variability in three ethnic groups as a basis for future genetic association studies. METHODS: Eighteen exonic SLCO1B1 single nucleotide polymorphisms (SNPs) were genotyped by PCR and RFLP analysis in 300 German, 94 Turkish, and 115 African subjects. Calculation of pairwise linkage disequilibrium and estimation of population haplotype frequencies were carried out, and haplotype block structure was determined. RESULTS: Only eight genotyped SNPs (c.388A&gt;G, c.411G&gt;A, c.463C&gt;A, c.521T&gt;C, c.571C&gt;T, c.597C&gt;T, c.1463G&gt;&gt;C, c.1929A&gt;C) were found in at least one of our German, Turkish, or African samples. A total of 12 haplotypes with a frequency &gt;or=1% in at least one of the three populations could be inferred. Between the Caucasian and African samples, significant differences in sequence variability were observed leading to a different haplotype profile in these populations. CONCLUSION: Our results demonstrate a high sequence variability of OATP1B1 within different popuations. In the future, distinct haplotypes should be taken into account when studying the effect of OATP1B1 on drugs in different populations.</p>
</dd>
]]></content:encoded>
			<wfw:commentRss>http://polymorphisms.info/polymorphisms/comparison-of-slco1b1-sequence-variability-among-german-turkish-and-african-populations.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>beta(1) and beta(2)-Adrenergic Receptor Polymorphisms and Idiopathic Ventricular Arrhythmias.</title>
		<link>http://polymorphisms.info/polymorphisms/beta1-and-beta2-adrenergic-receptor-polymorphisms-and-idiopathic-ventricular-arrhythmias.html</link>
		<comments>http://polymorphisms.info/polymorphisms/beta1-and-beta2-adrenergic-receptor-polymorphisms-and-idiopathic-ventricular-arrhythmias.html#comments</comments>
		<pubDate>Wed, 03 Sep 2008 09:22:18 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Adrenergic Receptor]]></category>
		<category><![CDATA[polymorphisms]]></category>
		<category><![CDATA[Activation]]></category>
		<category><![CDATA[adrenergic receptors]]></category>
		<category><![CDATA[Anatolian]]></category>
		<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Cetintas]]></category>
		<category><![CDATA[Electrophysiol]]></category>
		<category><![CDATA[equilibrium results]]></category>
		<category><![CDATA[eroglu]]></category>
		<category><![CDATA[gender]]></category>
		<category><![CDATA[genotype]]></category>
		<category><![CDATA[Gln]]></category>
		<category><![CDATA[Glu]]></category>
		<category><![CDATA[Gly]]></category>
		<category><![CDATA[haplotypes]]></category>
		<category><![CDATA[hardy weinberg equilibrium]]></category>
		<category><![CDATA[Hasdemir]]></category>
		<category><![CDATA[heart]]></category>
		<category><![CDATA[Idiopathic]]></category>
		<category><![CDATA[J Cardiovasc]]></category>
		<category><![CDATA[j cardiovasc electrophysiol]]></category>
		<category><![CDATA[Kayikcioglu]]></category>
		<category><![CDATA[Methods]]></category>
		<category><![CDATA[nucleotide]]></category>
		<category><![CDATA[patient population]]></category>
		<category><![CDATA[Payzin]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[PVC]]></category>
		<category><![CDATA[single nucleotide polymorphisms]]></category>
		<category><![CDATA[sympathetic tone]]></category>
		<category><![CDATA[tachycardia]]></category>
		<category><![CDATA[Tetik]]></category>
		<category><![CDATA[total]]></category>
		<category><![CDATA[unrelated patients]]></category>

		<guid isPermaLink="false">http://polymorphisms.info/?p=170</guid>
		<description><![CDATA[J Cardiovasc Electrophysiol. 2008 May 9. [Epub ahead of print]

Ulucan C, Cetintas V, Tetik A, Eroglu Z, Kayikcioglu M, Can LH, Payzin S, Aydin M, Hasdemir C.
Department of Cardiology, Ege University School of Medicine, Izmir, Turkey.
Introduction: Idiopathic ventricular arrhythmias commonly refer to ventricular tachycardia (VT) and/or frequent/monomorphic premature ventricular contractions (PVC) in patients with structurally [...]]]></description>
			<content:encoded><![CDATA[<p><span title="Journal of cardiovascular electrophysiology."><a href="javascript:AL_get(this, 'jour', 'J Cardiovasc Electrophysiol.');">J Cardiovasc Electrophysiol.</a></span> 2008 May 9. [Epub ahead of print]<script type="text/javascript"></script></p>
<dd class="abstract">
<div class="authors"><!--AuthorList--><a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Ulucan%20C%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Ulucan C</strong></a>, <a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Cetintas%20V%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Cetintas V</strong></a>, <a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Tetik%20A%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Tetik A</strong></a>, <a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Eroglu%20Z%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Eroglu Z</strong></a>, <a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Kayikcioglu%20M%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Kayikcioglu M</strong></a>, <a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Can%20LH%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Can LH</strong></a>, <a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Payzin%20S%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Payzin S</strong></a>, <a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Aydin%20M%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Aydin M</strong></a>, <a href="http://polymorphisms.info/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Hasdemir%20C%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><strong>Hasdemir C</strong></a>.</div>
<p class="affiliation">Department of Cardiology, Ege University School of Medicine, Izmir, Turkey.</p>
<p class="abstract" style="text-align: justify;">Introduction: Idiopathic ventricular arrhythmias commonly refer to ventricular tachycardia (VT) and/or frequent/monomorphic premature ventricular contractions (PVC) in patients with structurally normal heart. Activation of sympathetic tone has been shown to play an important role in the provocation and maintenance of these arrhythmias. We investigated whether common single nucleotide polymorphisms in the beta(1) and beta(2)-adrenergic receptors are associated with idiopathic ventricular arrhythmias. Methods: A total of 143 unrelated patients presenting with idiopathic ventricular arrhythmias were prospectively included in a case-control association study. Patient population was matched by age and gender to the unrelated, healthy control subjects (N = 307). All study subjects were of Turkish (Anatolian Caucasian) descent. Allele and genotype frequencies of the Gly389Arg and Ser49Gly polymorphisms of the beta(1)-adrenergic receptor and Arg16Gly, Gln27Glu, and Thr164Ile polymorphisms of the beta(2)-adrenergic receptor were compared between patient population and control subjects. The genotype frequencies were in Hardy-Weinberg equilibrium. Results: Patients with idiopathic ventricular arrhythmias had higher frequency of Arg389Arg genotype (22.4% vs 1.6%, P &lt; 0.001), Arg389Gly49 (5.24% vs 0.73%, P = 0.005), and Arg389Ser49 (36.7% vs 13.6%, P &lt; 0.001) haplotypes of the beta(1)-adrenergic receptor, and higher frequency of Gly16Gly (31.5% vs 13.4%, P &lt; 0.001), Glu27Glu genotypes (18.2% vs 10.1%, P = 0.006) and Gly16Gln27Thr164 (15.3% vs 7.4%, P = 0.002), Gly16Glu27Thr164 (13.1% vs 7%, P = 0.004), and Gly16Glu27Ile164 (13.2% vs 6%, P = 0.002) haplotypes of the beta(2)-adrenergic receptor compared to control subjects. Conclusion: Our data suggest that common single nucleotide polymorphisms in the beta(1) and beta(2)-adrenergic receptors are significantly associated with idiopathic ventricular arrhythmias in Turkish population.</p>
</dd>
]]></content:encoded>
			<wfw:commentRss>http://polymorphisms.info/polymorphisms/beta1-and-beta2-adrenergic-receptor-polymorphisms-and-idiopathic-ventricular-arrhythmias.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Arg194trp And Arg399gln Polymorphisms Of The Dna Repair Gene X-ray Repair Cross-complementing</title>
		<link>http://polymorphisms.info/polymorphisms/arg194trp-and-arg399gln-polymorphisms-of-the-dna-repair-gene-x-ray-repair-cross-complementing.html</link>
		<comments>http://polymorphisms.info/polymorphisms/arg194trp-and-arg399gln-polymorphisms-of-the-dna-repair-gene-x-ray-repair-cross-complementing.html#comments</comments>
		<pubDate>Sun, 31 Aug 2008 20:12:12 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[polymorphisms]]></category>
		<category><![CDATA[aBiyofizik]]></category>
		<category><![CDATA[alkylating agents]]></category>
		<category><![CDATA[alleles]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[chinese populations]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[dna repair]]></category>
		<category><![CDATA[dna strand]]></category>
		<category><![CDATA[Emin]]></category>
		<category><![CDATA[Fakültesi]]></category>
		<category><![CDATA[Gene X-]]></category>
		<category><![CDATA[genetic disease]]></category>
		<category><![CDATA[GÖKDO]]></category>
		<category><![CDATA[integrity]]></category>
		<category><![CDATA[italian american]]></category>
		<category><![CDATA[J Med]]></category>
		<category><![CDATA[Kaan]]></category>
		<category><![CDATA[Klinikleri]]></category>
		<category><![CDATA[Mersin]]></category>
		<category><![CDATA[Methods]]></category>
		<category><![CDATA[Nurten]]></category>
		<category><![CDATA[oxygen]]></category>
		<category><![CDATA[polymerase chain reaction]]></category>
		<category><![CDATA[polymerase chain reaction pcr]]></category>
		<category><![CDATA[polymorphism]]></category>
		<category><![CDATA[protection]]></category>
		<category><![CDATA[ray]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[SAVA]]></category>
		<category><![CDATA[Sci]]></category>
		<category><![CDATA[Turkiye]]></category>
		<category><![CDATA[turkiye klinikleri]]></category>
		<category><![CDATA[Üniversitesi]]></category>

		<guid isPermaLink="false">http://polymorphisms.info/?p=166</guid>
		<description><![CDATA[Turkiye Klinikleri J Med Sci 2004, 24:573-578
Dr. Nurten ERDAL,a Dr. M. Emin ERDAL,b Dr. Kaan SAVAŞOĞLU,b Tuba GÖKDOĞANb
aBiyofizik AD, bTıbbi Biyoloji ve Genetik AD, Mersin Üniversitesi Tıp Fakültesi, MERSİN
 

Objective: X-ray repair cross-complementing (XRCC1) is one of the genes responsible for the DNA repair mechanism. It plays an important role in the protection of the integrity [...]]]></description>
			<content:encoded><![CDATA[<p><strong>Turkiye Klinikleri J Med Sci 2004, 24:573-578</strong></p>
<p><span class="normal_10">Dr. Nurten ERDAL,<sup>a</sup> Dr. M. Emin ERDAL,<sup>b</sup> Dr. Kaan SAVAŞOĞLU,<sup>b</sup> Tuba GÖKDOĞAN<sup>b</sup><br />
<sup>a</sup>Biyofizik AD, <sup>b</sup>Tıbbi Biyoloji ve Genetik AD, Mersin Üniversitesi Tıp Fakültesi, MERSİN</span></p>
<p> </p>
<p style="TEXT-ALIGN: justify">
<span class="normal_9"><strong>Objective:</strong> X-ray repair cross-complementing (XRCC1) is one of the genes responsible for the DNA repair mechanism. It plays an important role in the protection of the integrity of the genome and in the development of mutations in hereditary genetic disease and cancer. The XRCC1 gene codes proteins which play a role in the repair of DNA strand breaks caused by active oxygen, ionization and alkylating agents. Functional polymorphism of the XRCC1 gene is a contributing factor for changes in the DNA repair mechanism, which is a risk factor for cancer.<br />
<strong>Material and Methods:</strong> Codon 194 (Arg→Trp) and codon 399 (Arg→Gln) are functional polymorphisms in the XRCC1 gene. These polymorphisms were determined by Polymerase Chain Reaction (PCR) and Restriction Fragment Length Polymorphism (RFLP) in unrelated 75 healty persons. These results were compared with other related investigation results.<br />
<strong>Results:</strong> Frequencies of Arg and Trp alleles of codon 194 were shown to be 0.94 and 0.06, respectively. However, frequencies of Arg and Gln alleles of codon 399 were 0.65 and 0.35.<br />
<strong>Conclusion:</strong> With regard to Arg194Trp functional polymorphisms of the XRCC1 gene, our results of allele frequencies are similar to those found in related investigations in American (caucasian) and Colombian populations, but different from others in Taiwanese, American (African-American) and Chinese populations. The other XRCC1 gene polymorphism examined, Arg399Gln, manifested frequencies similar to those found in investigations in Italian, American (caucasian), Finnish and Colombian populations; however, our results are different from those involving Taiwanese, American (African-American), Colombian, Asian and Chinese populations. The alleles at risk appear to vary in different populations and according to cancer type. Therefore, it is very important to determine those alleles exhibiting a heightened cancer risk in our population.</span></p>
<p><span class="normal_10"><strong>Keywords: </strong>Genes, polymorphism, XRCC1 protein</span></p>
<p><span class="normal_10"><strong>Turkiye Klinikleri J Med Sci 2004, 24:573-578</strong></span></p>
]]></content:encoded>
			<wfw:commentRss>http://polymorphisms.info/polymorphisms/arg194trp-and-arg399gln-polymorphisms-of-the-dna-repair-gene-x-ray-repair-cross-complementing.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

